

David E. Levy PhD
PROFESSOR OF PATHOLOGY AND MICROBIOLOGY
Dr Louis A Schneider Professorship in Molecular Pathology
Director, Molecular Oncology and Tumor Immunology Training Program
Faculty Liaison Director, Advanced Research Technologies

Personal Information:

Address (Work): Department of Pathology
New York University School of Medicine
550 First Avenue MSB531A
New York, NY 10016
(212) 263-8192 (v); (212) 263-8211 (f)
david.levy@med.nyu.edu
Twitter: @Levy_JakStatLab

Address (Home): 17 East 95th Street, Apt. 4F
New York, NY 10128

Educational Background:

Doctor of Philosophy, 1985
Division of Biology
California Institute of Technology
Pasadena, CA

Bachelor of Arts, 1974
Department of Biology
University of Tennessee
Knoxville, TN

Professional Experience:

Assoc. Dean for Advanced Technology	2016 - 2018
Assoc. Dean for Collaborative Science	2009 – 2016
Dr. Louis A. Schneider Chair in Molecular Pathology	2002 – present
Vice Chairman for Science, Department of Pathology	2006 – 2010
Professor of Microbiology	2002 – present
Professor of Pathology	1999 – present
Associate Professor of Pathology with Tenure	1995 – 1999
Assistant Professor of Pathology	1988 – 1995
Associate Director, NYU Perlmutter Cancer Institute	2011 – 2018
Director, Molecular Oncology and Immunology Program	2010 – present
Assoc. Director, Pathobiology Graduate Training Program	2006 – 2010
Assoc. Director, Cell & Mol. Biology Training Program	1998 – 2007
Assoc. Director, Virus-Host Interactions Program	2000 – present
Sackler Institute for Graduate Biomedical Sciences, NYU	1989 – present
Adjunct Faculty, Rockefeller University	1988

Postdoctoral Associate	1987 – 1988
Postdoctoral Fellow	1984 – 1987
Laboratory of Molecular Cell Biology Rockefeller University	
Graduate Student	1978 – 1984
Division of Biology California Institute of Technology	
Visiting Graduate Fellow	1981 – 1984
Department of Molecular Biology The Scripps Research Institute	
Research Assistant	1977 – 1978
Memorial Research Center University of Tennessee	
Research Assistant	1975 – 1977
Molecular Anatomy Program Oak Ridge National Laboratory	

Academic Honors and Service:

Co-organizer, CSH Conf., "STATs: From Basic to Clinical Oncology"	2020
Co-organizer, CSH Conf., "STATs: From Basic to Clinical Oncology"	2017
Co-organizer, Banbury Conf., "STAT3 in Cancer: How can it be inhibited?"	2016
Scientific Committee, ICIS Intl. Meeting, Bamberg, Germany	2015
Scientific Committee, ISICR-ICS Intl. Meeting, San Francisco	2013
Co-chair, The Jak-STAT Pathway, NIH	2011
Scientific Committee, ISICR Intl. Meeting, Lisbon	2009
Elected Fellow of the AAAS	2009
Co-chair, Keystone Symposium on Jak-Stat Signaling	2007
Scientific Committee, ISICR Intl. Meeting, Shanghai	2005
Co-chair, Keystone Symposium on Jak-Stat Signaling	2004
Dr. Louis A. Schneider Chair in Molecular Pathology	2002 – pres.
Milstein Award of the ISICR	2002
Co-chair, First Keystone Symposium on Jak-Stat Signaling	1998
Scientific Committee, Joint ICS/ISICR Intl. Meeting	1998
Hirschl Trust Career Scientist	1995 – 1999
Whitehead Presidential Fellow, NYU	1992 – 1993
Pew Scholar in the Biomedical Sciences	1991 – 1995
Investigator, Cancer Research Institute	1990 – 1994
ACS Junior Faculty Research Award	1990 – 1992
Kaplan Scholar, Rita & Stanley H. Kaplan Cancer Center	1989 – 1992
NIH Individual Postdoctoral Fellowship	1985 – 1987
NIH Predoctoral Training Fellowship	1978 – 1983
Institute Scholarship, Caltech	1978 – 1983

Member, NYU IACUC	1996 – 2012
Chair, NYU IACUC	2001 – 2012
Chair, NYU ESCRO Committee	2009 – 2011
Editor, <i>Journal of Cellular Physiology</i>	2001 – 2002
Editor, <i>Molecular and Cellular Biology</i>	2002 – 2017
Editorial Boards:	
<i>Journal of Interferon Research</i>	1992 – 1995
<i>Molecular and Cellular Biology</i>	1993 – 2007
<i>Journal of Biological Chemistry</i>	1996 – 2000
<i>J. IFN & Cytokine Research</i>	1998 – 2011
<i>Cytokine and Growth Factor Reviews</i>	2000 – 2007
<i>Signal Transduction</i>	2002 – present
<i>Immunity</i>	2005 – present
<i>Jak-STAT</i>	2012 – present

Scientific Reviews and Study Sections:

<i>Arthritis Foundation Grants and Fellowships</i>	1992 - 1995
<i>NYU Research Bridging Support</i>	1994 - 2012
<i>ACS Institutional Committee</i>	1994 – 2000
<i>NIH Cell Biology & Physiology 2</i>	1997 – 1998
<i>NIH CSD (formerly CDF3)</i>	2001 – 2005
<i>NCI P01 Review (Chair)</i>	2004
<i>NCI Clinical Cluster Review</i>	2006
<i>NIAID P01 Review</i>	2006
<i>NIAMS Basic Science Review</i>	2007
<i>NIAID P01 Review Panel (Chair)</i>	2011 – 2012
<i>NIAID U19 Reviews</i>	2013
<i>NIAID Special Emphasis Panel</i>	2015
<i>NCI T32 Review Panel</i>	2015
<i>NCI Intramural Research Review Panel</i>	2017
<i>SFB-F061 External SAB, Vienna, Austria</i>	2017 – pres.
<i>NCI Subcommittee F Review Panel</i>	2018
<i>Chair, Lab11 Therapeutics SAB</i>	2018 – pres.
<i>Chair, NIH F07-U20 Study Section</i>	2019 – pres.
<i>NCI Intramural Research Review Panel</i>	2021
<i>French National Cancer Institute (INCa) Review Panel</i>	2021
<i>Medical University of Vienna Faculty Promotions Review</i>	2021

Manuscripts:

1. Eveleigh JW and Levy DE (1977) Immunochemical characteristics and preparative applications of agarose-based immunosorbents. *J. Solid-Phase Biochem.* **2**: 45-78.
2. Levy DE and Eveleigh JW (1978) Reversed immunosorbents: a simple method for specific antibody immobilization. *J. Immunol. Methods* **22**: 131-142.
3. Levy DE, Horner AA and Solomon A (1981) Immunoglobulin sulfated polysaccharide interactions: binding of agaropectin and heparin by human IgG proteins. *J. Exp. Med.* **153**: 883-896.

4. Levy DE, Lerner RA and Wilson MC (1982) A genetic locus regulates the expression of tissue-specific mRNAs from multiple transcription units. *Proc. Natl. Acad. Sci. USA* **79**: 5823-5827.
5. Levy DE, Lerner RA and Wilson MC (1985) The Gv-1 locus coordinately regulates the expression of multiple endogenous murine retroviruses. *Cell* **41**: 289-299.
6. Levy DE, Lerner RA and Wilson MC (1985) Normal expression of polymorphic endogenous retroviral RNA containing segments identical to mink cell focus forming virus. *J. Virol.* **56**: 691-700.
7. Koffler R, Noonan D, Levy D, Wilson M, Moller N, Dixon F and Theophilopoulos A (1985) Genetic elements utilized for a murine lupus anti-DNA autoantibody are closely related to those for antibodies to exogenous antigens. *J. Exp. Med.* **161**: 805-815.
8. Levy DE, Lerner A, Chaudhuri A, Babiss L and Darnell JE Jr (1986) Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region. *Proc. Natl. Acad. Sci. USA* **83**: 8929-8933.
9. Levy DE, McKinnon RD, Brolaski MN, Gautsch JW and Wilson MC (1987) The 3' long terminal repeat of a transcribed yet defective endogenous retroviral sequence is a competent promoter of transcription. *J. Virol.* **61**: 1261-1265.
10. Reich N, Evans B, Levy D, Fahey D, Knight E and Darnell J Jr (1987) Interferon-induced transcription of a gene encoding a 15 kDa protein depends on an upstream enhancer element. *Proc. Natl. Acad. Sci. USA* **84**: 6394-6398.
11. Reich N, Pine R, Levy D and Darnell J Jr (1988) Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. *J. Virol.* **62**: 114-119.
12. Pine R, Levy DE, Reich N and Darnell JE Jr (1988) Transcriptional stimulation by CaPO₄ precipitates. *Nucl. Acids Res.* **16**: 1371-1378.
13. Levy DE, Kessler DS, Pine R, Reich N and Darnell JE Jr (1988) Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. *Genes Develop.* **2**: 383-393.
14. Kessler DS, Levy DE and Darnell JE Jr (1988) One DNA binding site in interferon stimulated gene promoters for two interferon induced nuclear factors. *Proc. Natl. Acad. Sci. USA* **85**: 8521-8525.
15. Kessler DS, Pine R, Pfeffer L, Levy DE and Darnell JE Jr (1988) Cells resistant to the physiological effects of interferon are defective in the activation of a promoter binding factor. *EMBO J.* **7**: 3779-3783.
16. Decker T, Lew DJ, Cheng Y-SE, Levy DE and Darnell JE Jr (1989) Interactions of α - and γ -interferon in the transcriptional regulation of the gene encoding a guanylate-binding protein. *EMBO J.* **8**: 2009-2014.
17. Levy DE, Kessler DS, Pine RI and Darnell JE Jr (1989) Cytoplasmic activation of ISGF3, the positive activator of interferon- α stimulated transcripton, reconstituted *in vitro*. *Genes Develop.* **3**: 1362-1371.

18. Raj NBK, Engelhardt J, Au W-C, Levy DE and Pitha PM (1989) Virus infection and interferon can activate gene expression through a single synthetic element but endogenous genes show distinct regulation. *J. Biol. Chem.* **264**: 16658-16666.
19. Levy DE, Lew DJ, Decker T, Kessler DS and Darnell JE Jr (1990) Synergistic interaction between interferon- α and interferon- γ through induced synthesis of one subunit of the transcription factor ISGF3. *EMBO J.* **9**: 1105-1111.
20. Pine R, Decker T, Kessler DS, Levy DE and Darnell JE Jr (1990) Purification and cloning of Interferon-Stimulated Gene Factor 2: ISGF2 (IRF-1) can bind to the promoters of both interferon- β and interferon-stimulated genes but is not a primary transcriptional activator. *Mol. Cell. Biol.* **10**: 2448-2457.
21. Kessler DS, Veals SA, Fu X-Y and Levy DE (1990) IFN α regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. *Genes Develop.* **4**: 1753-1765.
22. Fu X-Y, Kessler DS, Veals SA, Levy DE and Darnell JE Jr (1990). ISGF3, the transcriptional activator induced by interferon- α , consists of multiple interacting polypeptide chains. *Proc. Natl. Acad. Sci. USA* **87**: 8555-8559.
23. Levy DE and Darnell JE Jr. (1990) Interferon-dependent transcriptional activation: signal transduction without second messenger involvement? *New Biologist* **2**: 923-928.
24. Kessler DS and Levy DE (1991) Protein kinase activity required for an early step in interferon- α signalling. *J. Biol. Chem.* **266**: 23471-23476.
25. Veals SA, Schindler C, Leonard D, Fu X-Y, Aebersold RH, Darnell JE Jr and Levy DE (1992) Subunit of an IFN α -responsive transcription factor is related to IRF and Myb families of DNA binding proteins. *Mol. Cell. Biol.* **12**: 3315-3324.
26. Veals SA, Sta. Maria T and Levy DE (1993) Two domains of ISGF3 γ that mediate protein-DNA and protein-protein interaction during transcription factor assembly contribute to DNA-binding specificity. *Mol. Cell. Biol.* **13**: 196-206.
27. Parrington J, Rogers NC, Gewert DR, Pine R, Veals SA, Levy DE, Stark GR and Kerr, IM (1993) The interferon-stimulatable response elements of two human genes detect overlapping sets of transcription factors. *Eur. J. Biochem.* **214**: 617-626.
28. Silvennoinen O, Schindler C, Schlessinger J and Levy DE (1993) Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. *Science* **261**: 1736-1739.
29. Silvennoinen O, Ihle J, Schlessinger J and Levy DE (1993) Interferon-induced nuclear signaling by JAK protein tyrosine kinases. *Nature* **366**: 583-585.
30. Rothman P, Kreider B, Levy D, Wegenka U, Eilers A, Decker T, Horn F, Kashleva H, Ihle J and Schindler C (1994) Cytokines signal through tyrosine phosphorylation of a family of related transcription factors. *Immunity* **1**: 457-468.
31. Lamb P, Kessler LJ, Suto C, Levy DE, Seidel HM, Stein RB and Rosen J (1994) Rapid activation of proteins that interact with the interferon gamma activation site in response to multiple cytokines. *Blood* **83**: 2063-2071.
32. Bovolenta C, Driggers PH, Marks MS, Medin JA, Politis AD, Vogel SN, Levy DE, Sagakuchi K, Appella E, Coligan JE and Ozato K (1994) Molecular interactions

- between ICSBP and members of the interferon regulatory factor family. *Proc. Natl. Acad. Sci. USA* **91**:5046-5050.
33. Seeger D, Strehlow I, Klose B, Levy DE, Schindler C and Decker T (1994) A novel IFN α regulated DNA-binding protein participates in the regulation of the IFP53/tryptophanyl-tRNA synthetase gene. *J. Biol. Chem.* **269**: 8590-8595.
 34. Raz R, Durbin JE and Levy DE (1994) Acute phase response factor and additional members of the ISGF3 family integrate diverse signals from cytokines, interferons, and growth factors. *J. Biol. Chem.* **269**: 24391-24395.
 35. Campbell GS, Meyer DJ, Raz R, Levy DE, Schwartz J and Carter SC (1995) Activation of acute phase response factor (APRF)/Stat3 transcription factor by growth hormone. *J Biol Chem* **270**: 39743979.
 36. Bluysen HA, Muzaffar R, Vlieststra RJ, van, der, Made, Ac, Leung S, Stark GR, Kerr IM, Trapman J and Levy DE (1995) Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. *Proc Natl Acad Sci USA* **92**: 5645-5649.
 37. Gouilleux F, Pallard C, Dusanter-Fourt I, Wakao H, Haldosen L-A, Norstedt G, Levy DE and Groner B (1995) Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. *EMBO J* **14**: 2005-2014.
 38. Pallard C, Gouilleux F, Benit L, Cocault L, Souyri M, Levy D, Groner B, Gisselbrecht S and Dusanter FI (1995) Thrombopoietin activates a STAT5-like factor in hematopoietic cells. *EMBO J* **14**: 2847-56.
 39. Raz R, Cheung K, Ling L and Levy DE (1995) Three distinct loci on human chromosome 21 contribute to interferon α/β responsiveness. *Somat. Cell Mol. Genet.* **21**: 139-145.
 40. Henttinen T, Levy DE, Silvennoinen O and Hurme M (1995) Activation of the signal transducer and transcription (STAT) signaling pathway in primary T cell response. Critical role for IL-6 (1995) *J. Immunol.* **155**: 4582-4587.
 41. Levy JB, Schindler C, Raz R, Levy DE, Baron R and Horowitz MC (1996) Activation of the Jak-Stat signal transduction pathway by oncostatin-M in cultured human and mouse osteoblasts. *Endocrinology* **137**: 1159-1165.
 42. Leaman DW, Pisharody S, Flickinger TW, Commane MA, Schlessinger J, Kerr IM, Levy DE, Stark GR (1996) Roles of Jaks in activation of Stats and stimulation of *c-fos* gene expression by epidermal growth factor. *Mol. Cell. Biol.* **16**: 369-375.
 43. Nguyen NY, Sackett D, Hirata RDC, Levy DE, Enterline JC, Bekisz JB and Hirata MH (1996) Isolation of a biologically active soluble human interferon-alpha receptor-GST fusion protein expressed in *Escherichia coli*. *J. Interferon Cytoline Res.* **16**: 835-844.
 44. Durbin JE, Hackenmiller R, Simon MC and Levy DE (1996) Targeted Disruption of the mouse *Stat1* gene results in compromised innate immunity to viral disease. *Cell* **84**: 443-450.
 45. Nguyen NY, Sackett D, Hirata RDC, Levy DE, Enterline JC, Bekisz JB and Hirata MH (1996) Isolation of a biologically active soluble human Interferon- α receptor-GST fusion protein expressed in *Escherichia coli*. *J. IFN Cyt. Res.* **16**: 835-844.

46. Bluysen HAR and Levy DE (1997) Stat2 is a transcriptional activator that requires sequence-specific contacts provided by Stat1 and p48 for stable interaction with DNA. *J. Biol. Chem.* **272**: 4600-4605.
47. Lee C-K, Bluysen HAR and Levy DE (1997) Regulation of IFN- α responsiveness by the duration of JAK kinase activity. *J. Biol. Chem.* **272**: 21872-21877.
48. Hirata RDC, Hirata MH, Levy DE and Nguyen NY (1997) Optimized production of the soluble human interferon α receptor (IFNAR) expressed in *E. coli* *Biotech. Tech.* **11**: 301-305.
49. Matikainen S, Ronni T, Lehtonen A, Sareneva T, Melén K, Nordling S, Levy DE and Julkunen I (1997) Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. *Cell Growth Diff.* **8**: 687-698.
50. Fernandez-Sesma A, Peluso RW, Bai X, Schulman JL, Levy DE and Moran TM (1998) SEB T cells and bispecific antibody inhibit VSV replication. *J. Immunol.* **160**: 1841-1849.
51. García-Sastre A, Durbin RK, Zheng H, Palese P, Gertner R, Levy DE and Durbin JE (1998) Role of interferon in influenza virus tissue tropism. *J. Virol.* **72**: 8550-8558.
52. Zheng P, Guo Y, Niu Q, Levy DE, Dyck J, Lu S, Sheiman LA and Liu Y (1998) Proto-oncogene PML controls multiple genes devoted to MHC class I antigen presentation. *Nature* **396**: 373-376.
53. Marié I, Durbin JE and Levy DE (1998) Differential viral induction of distinct alpha-interferon genes by positive feedback through interferon regulatory factor-7. *EMBO J.* **17**: 6660-6669.
54. García-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P and Muster T (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. *Virology* **252**: 324-330.
55. Nadeau OW, Domanski P, Usacheva A, Uddin S, Plataniás LC, Pitha P, Raz R, Levy DE, Majchrzak B, Fish E and Colamonici OR (1999) The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation. *J. Biol. Chem.* **274**: 4045-4052.
56. Raz R, Lee CK, Cannizzaro LA, d'Eustachio P and Levy DE (1998) Essential role of STAT3 for embryonic stem cell pluripotency. *Proc. Natl. Acad. Sci. USA* **96**: 2846-2851.
57. Bottrel RLA, Yang YL, Levy DE, Tomai M and Reis LFL (1998) Induction of IL-6, interferon, and interferon-stimulated genes by the immunoresponse modifier Imiquimod requires Stat1. *Antimicrobial Agents and Chemotherapy* **43**: 856-861.
58. Sahni M, Ambrosetti D, Mansukhani A, Gertner R, Levy DE and Basilico C (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT1 pathway. *Genes Dev.* **13**: 1361-1366.

59. Paulson M, Pisharody S, Pan L, Guadagno S, Mui A and Levy DE (1999) Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. *J. Biol. Chem.* **274**: 25343-25349.
60. Goodman AR, Levy DE, Reis LFL and Vilcek J (2000) Differential regulation of TSG-14 expression in murine fibroblasts and peritoneal macrophages. *J. Leuk. Biol.* **67**: 387-395.
61. Lee CK, Gimeno R and Levy DE (1999) Differential regulation of constitutive MHC class I expression in T and B lymphocytes. *J. Exp. Med.* **190**: 1451-1463.
62. Lee CK, Smith E, Gimeno R, Gertner R and Levy DE (2000) Stat1 affects lymphocyte survival, proliferation and differentiation independent of its role downstream of IFN γ . *J. Immunol.* **164**: 1286-1292.
63. Durbin JE, Fernandez-Sesma A, Lee CK, Rao TD, Frey AB, Moran TM, Vukmanovic S, García-Sastre A and Levy DE (2000) Type I interferon modulates innate and specific anti-viral immunity. *J. Immunol.* **164**: 4220-4228.
64. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. (2000) Mechanism of STAT3 activation by insulin-like growth factor I receptor. *J. Biol. Chem.* **275**: 15099-15105.
65. Weiden M, Tanaka N, Qiao Y, Zhao BY, Honda Y, Nakata K, Canova A, Levy DE, Rom WN, Pine R. (2000) Differentiation of monocytes to macrophages switches the Mycobacterium tuberculosis effect on HIV-1 replication from stimulation to inhibition: modulation of interferon response and CCAAT/enhancer binding protein beta expression. *J. Immunol.* **165**: 2028-2039.
66. Lee CK, Gimeno R, Gertner R, Rao DT, Frey A and Levy DE (2000) Distinct requirements for IFNs and STAT1 in natural killer cell function. *J. Immunol.*, **165**: 3571-3577.
67. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, Lee C-K, Gertner R, Kitamura T, Frantsve J, Anastasiadou E, Loh ML, Levy DE, Ihle JN, Gilliland DG (2000) Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. *Mol. Cell* **6**: 693-704.
68. Marié I, Smith E, Prakash A, Levy DE (2000) Phosphorylation-induced dimerization of interferon regulatory factor 7 unmasks DNA binding and a bipartite transactivation domain. *Mol. Cell. Biol.* **20**: 8803-8814.
69. Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Muller M, Decker T (2001) Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. *EMBO J.* **20**: 91-100.
70. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy DE, Horvath CM, Ronai R (2001) Cooperation between STAT3 and c-Jun suppresses Fas transcription. *Mol. Cell* **7**: 517-528.
71. Smith E, Marie I, Prakash A, Garcia-Sastre A, Levy DE (2001) IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or I κ B kinase but is blocked by vaccinia virus E3L protein. *J. Biol. Chem.* **276**:8 951-8957.

72. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N, Gretch DR (2001) Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. *J. Virol.* **75**: 6095-6106.
73. Sahni M, Raz R, Coffin JD, Levy DE, Basilio C (2001) STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. *Development* **128**: 2119-2129.
74. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G (2001) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. *Oncogene* **21**: 1038-47.
75. Paulson M, Press C, Smith E, Tanese N, Levy DE (2001) IFN Stimulated Transcription Through a TBP-Free Acetyltransferase Complex Escapes Viral Shutoff. *Nature Cell Biol.* **4**: 140-147.
76. Enninga J, Levy DE, Blobel G, Fontoura BMA (2002) Role of nucleoporin induction in releasing an mRNA nuclear export block. *Science* **295**: 1523-1525.
77. Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y (2002) A Kaposi's Sarcoma-Associated Hesperiviral Protein Inhibits Virus Mediated Induction of Type I Interferon by Blocking IRF-7 Phosphorylation and Nuclear Accumulation. *Proc. Natl. Acad. Sci USA* **99**: 5573-5578.
78. Humphreys RC, Bieri B, Zhao L., Raz R, Levy DE, Hennighausen L (2002) Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. *Endocrinology* **143**: 3641-3650.
79. Lee CK, Raz R, Gimeno R, Wistinghausen B, Takeshita K, DePinho R, Levy DE (2002) STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. *Immunity* **17**: 63-72.
80. Caillaud A, Prakash A, Smith E, Masumi A, Hovanessian AG, Levy DE, and Marie IJ. (2002) Acetylation of interferon regulatory factor-7 by PCAF impairs its DNA binding. *J. Biol. Chem.* **277**: 49417-49421.
81. Stockinger, S., Materna, T., Stoiber, D., Bayr, L., Steinborn, R., Unger, H., Cossart, P., Chakraborty, T., Levy, D. E., Müller, M., and Decker, T. (2002). Production of type I interferon sensitizes macrophages to cell death induced by *Listeria monocytogenes*. *J. Immunol.* **169**: 6522-6529.
82. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshauser G., Baccarini M., Donabauer B., Reichart U., Kolbe T., Bogdan C., Leanderson T., Levy D., Decker T, Muller M. (2003). Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. *Nat. Immunol.* **4**:471-477.
83. Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M, Nebreda AR, Fish EN, Platanius LC (2004). Role of p38alpha Map kinase in Type I interferon signaling. *J. Biol. Chem.* **279**, 970-979.
84. Rankin EB, Yu D, Jiang J, Shen H, X Pearce EJ, Goldschmidt MH, Levy DE, Golovkina TV, Hunter CA, Thomas-Tikhonenko A. (2003) An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth. *Can. Biol. Therap.* **2**: 687-693.

85. Usacheva A, Tian X, Sandoval R, Salvi D, Levy DE & Colamonici OR (2003). The WD motif-containing protein RACK-1 functions as a scaffold protein within the type I IFN receptor-signaling complex. *J. Immunol.* **171**: 2989-2994.
86. Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, Levy DE, Darnell JE Jr. (2004). Essential Role of STAT3 in Postnatal Survival and Growth Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation. *Mol. Cell. Biol.* **24**: 407-419.
87. Chesler DA, Dodard C, Lee GY, Levy DE, Reiss CS. (2004) Interferon-gamma-induced inhibition of neuronal vesicular stomatitis virus infection is STAT1 dependent. *J. Neurovirol.* **10**, 57-63.
88. Chang HM, Paulson M, Holko M, Rice CM, Williams BRG, Marié IJ, Levy DE (2004) Induction of Interferon-Stimulated Gene Expression and Antiviral Responses Require Protein Deacetylase Activity. *Proc. Natl. Acad. Sci. USA* **101**: 9578-9583.
89. Halupa A, Bailey M, Huang K, Iscove NN, Levy DE, Barber DL (2004) A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution. *Blood* **105**: 552-61.
90. Li Y, Batra S, Sassano A, Majchrzak B, Levy DE, Gaestel M, Fish ED, Davis RJ, Plataniias LC (2005) Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons. *J. Biol. Chem.* **280**:10001-10.
91. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR (2005) Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. *Cancer Res.* **65**:939-47.
92. Caillaud A, Hovanessian AG, Levy DE & Marie IJ (2005) Regulatory Serine Residues Mediate Phosphorylation-dependent and Phosphorylation-independent Activation of Interferon Regulatory Factor 7. *J. Biol. Chem.* **280**: 17671-17677.
93. Prakash A, Smith E, Lee CK, Levy DE (2005) Tissue-specific positive feedback requirements for production of type I interferon following virus infection. *J. Biol. Chem.* **280**: 18651-18657.
94. Shen Y, La Perle KM, Levy DE, Darnell JE Jr (2005) Reduced STAT3 activity in mice mimics clinical disease syndromes. *Biochem, Biophys. Res. Comm.* **330**: 305-309.
95. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras J, Levy DE., Inghirami G (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a viable therapeutic target. *Nature Med.* **11**: 623-629.
96. Gimeno R, Lee CK, Schindler C, Levy DE (2005) Stat1 and Stat2 but not Stat3 Arbitrate Contradictory Growth Signals Elicited by IFN α / β in T Lymphocytes. *Mol. Cell. Biol.* **25**: 5456-5465.
97. Schlessinger K and Levy DE (2005) Malignant transformation but not normal cell growth depend on STAT3. *Cancer Res.* **65**: 5828-5834.
98. Gysemans CA, Ladriere L, Callewaert H, Rasschaert J, Flamez D, Levy DE, Matthys P, Eizirik DL & Mathieu C (2005). Disruption of the γ -Interferon Signaling Pathway at the Level of Signal Transducer and Activator of Transcription-1 Prevents Immune Destruction of β -cells. *Diabetes* **54**: 2396-2403.
99. Shi S, Nathan C, Hickey C, Blumenthal A, Gandotra S, Levy DE, Beutler B, Husemann J, Ehrt S (2005) Viable *Mycobacterium tuberculosis* induces expression of immunologically important genes in macrophages through a pathway

- independent of both TLR2 and TLR4 but dependent on IFN $\alpha\beta$ receptor and STAT1. *J. Immunol.* **175**: 3318-3328.
100. Wang Y and Levy DE (2006) *C. elegans* STAT cooperates with DAF-7/TGF- β signaling to repress dauer formation. *Curr. Bio.* **16**: 89-94.
 101. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM and Chen SH (2006) Gr-1⁺CD115⁺ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. *Cancer Res.* **66**: 1123-1131.
 102. Prakash A and Levy DE (2006) Regulation of IRF7 through cell type-specific protein stability. *Biochem. Biophys. Res. Comm.* **342**: 50-56.
 103. Zhang L, Badgwell DB, Bevers JJ, Schlessinger K, Murray PJ, Levy DE and Watowich SS (2006) IL-6 signaling via the STAT3/SOCS3 pathway: Functional analysis of the conserved STAT3 N-domain. *Mol. Cell. Biochem.* **288**: 179-189.
 104. Faria AMC, Levay A, Wang Y, Kaphorst AO, Rosa MLP, Nussenzweig DR, Balkan W, Chook YM, Levy DE and Fontoura BMA (2006) The Nucleoporin Nup96 is Required for Proper Expression of Interferon-Regulated Proteins and Functions. *Immunity* **24**: 295-304.
 105. Wang Y and Levy DE (2006) *C. elegans* STAT: evolution of a regulatory switch. *FASEB J.* **20**: 1641-1652.
 106. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M & Sexl V (2006). STAT1 acts as a tumor promoter for leukemia development. *Cancer Cell* **10**: 77-87.
 107. Chou WC, Levy DE and Lee CK (2006) STAT3 positively regulates an early step in B-cell development. *Blood* **108**: 3005-3011.
 108. Sun W, Snyder M, Levy DE and Zhang JJ (2006) Regulation of Stat3 transcriptional activity by the conserved LPMSP motif for OSM and IL-6 signaling. *FEBS Lett.* **580**: 5880-5884.
 109. Zeng R, Spolski R, Casas E, Zhu W, Levy DE and Leonard WJ (2007) The molecular basis of IL-21-mediated proliferation. *Blood* **109**: 4135-4142.
 110. Satterly N, Tsai PL, van Deursen J, Nussenzweig DR, Wang Y, Faria PA, Levay A, Levy DE and Fontoura BM (2007) Influenza virus targets the mRNA export machinery and the nuclear pore complex. *Proc. Natl. Acad. Sci USA* **14**: 1853-1858.
 111. Tseng J-C, Zheng Y, Yee H, Levy DE and Meruelo D (2007) Restricted tissue tropism and acquired resistance to Sindbis viral vector expression in the absence of innate and adaptive immunity. *Gene Therapy* **14**: 1166-1174.
 112. Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q, O'Malley JT, Kapur R, Levy DE, Kansas GS and Kaplan MH (2007) Stat3 and Stat4 direct development of IL-17-secreting Th cells. *J Immunol.* **178**: 4901-4907.
 113. Mahajan MA, Murray A, Levy DE and Samuels HH (2007) Nuclear receptor coregulator (NRC): mapping of the dimerization domain, activation of p53 and STAT-2, and identification of the activation domain AD2 necessary for nuclear receptor signaling. *Mol. Endocrinol.* **21**: 1822-1834.

114. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ and Littman DR (2007) IL-6 programs Th17 cell differentiation by promoting the sequential engagement of the IL-21 and IL-23 pathways. *Nat. Immunol.* **8**: 967-974.
115. Joo CH, Shin YC, Gack M, Wu L, Levy DE and Jung JU (2007) Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. *J. Virol.* **81**: 8282-8292.
116. Macdonald MR, Machlin ES, Albin OR and Levy DE (2007) The zinc-finger antiviral protein acts synergistically with an interferon-induced factor for maximal activity against alphaviruses. *J. Virol.* **81**: 13509-13518.
117. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, DePinho RA and Bonni A (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. *Genes Dev.* **22**: 449-462.
118. Chakraborty P, Wang Y, Wei JH, van Deursen J, Yu H, Malureanu L, Dasso M, Forbes DJ, Levy DE, Seemann J and Fontoura BM (2008) Nucleoporin levels regulate cell cycle progression and phase-specific gene expression. *Dev. Cell* **15**: 657-67.
119. Spolski R, Kim HP, Zhu W, Levy DE and Leonard WJ (2009) IL-21 mediates suppressive effects via its induction of IL-10. *J. Immunol.* **182**: 2859-2867.
120. Lu TC, Wang ZH, Feng X, Chuang PY, Fang W, Shen Y, Levy DE, Xiong H, Chen N and He JC (2009) Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. *Kidney Int.* **76**: 63-71.
121. Gough DJ, Corlett A, Schlessinger K, Wegrezy J, Lerner AC and Levy DE (2009) Mitochondrial Stat3 Supports Ras-Dependent Oncogenic Transformation. *Science* **324**: 1713-1716.
122. Feng X, Lu TC, Chuang PY, Fang W, Ratnam K, Xiong H, Ouyang X, Shen Y, Levy DE, Hyink D, Klotman M, D'Agati V, Iyengar R, Klotman PE and He JC (2009) Reduction of Stat3 Activity Attenuates HIV-Induced Kidney Injury. *J Am Soc Nephrol* **20**: 2138-2146.
123. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M and Muller WJ (2009) Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. *Cancer Res.* **69**: 6823-6830.
124. Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim HP, Oh J, Tunyaplin C, Carotta S, Donovan CE, Goldman ML, Taylor P, Ozato K, Levy DE, Nutt SL, Calame K and Leonard WJ (2009) Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. *Immunity* **31**: 941-52.
125. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE and Bromberg JS (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. *J. Immunol.* **182**: 259-73.
126. O'Malley JT, Sehra S, Thieu VT, Yu Q, Chang HC, Stritesky GL, Nguyen ET, Mathur AN, Levy DE and Kaplan MH (2009) Signal transducer and activator of transcription 4 limits the development of adaptive regulatory T cells. *Immunology* **127**: 587-95.

127. Xu J, Yang Y, Qiu G, Lal G, Wu Z, Levy DE, Ochando JC, Bromberg JS and Ding Y (2009) c-Maf regulates IL-10 expression during Th17 polarization. *J. Immunol.* **182**: 6226-36.
128. Gough DJ, Messina NL, Hii L, Gould JA, Sabapathy K, Robertson AP, Trapani JA, Levy DE, Hertzog PJ, Clarke CJ and Johnstone RW (2010) Functional crosstalk between type I and II interferon through the regulated expression of STAT1. *PLoS Biol.* **8**: e1000361. PMC2860501
129. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D and Littman DR (2010) A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. *Nature* **467**: 214-217.
130. Demaria M, Giorgi C, Lebedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, Wieckowski MR, Provero P, Pinton P and Poli V (2010) A STAT3-mediated metabolic switch is involved in tumor transformation and STAT3 addiction. *Aging* **2**: 823-842.
131. Stritesky GL, Muthukrishnan R, Sehra S, Goswami R, Pham D, Travers J, Nguyen ET, Levy DE and Kaplan MH (2011) The transcription factor STAT3 is required for T helper 2 cell development. *Immunity* **34**: 39-49.
132. Kaplan MH, Glosson NL, Stritesky GL, Yeh N, Kinzfohl J, Rohrabough SL, Goswami R, Pham D, Levy DE, Brutkiewicz RR, Blum JS, Cooper S, Hangoc G and Broxmeyer HE (2011) STAT3-dependent IL-21 production from T helper cells regulates hematopoietic progenitor cell homeostasis. *Blood*: **117**: 6198-6201.
133. O'Brien M, Manches O, Sabado RL, Jimenez Baranda S, Wang Y, Marie I, Rolnitzky L, Markowitz M, Margolis DM, Levy D and Bhardwaj N (2011). Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. *J. Clin. Invest.* **121**: 1088-1101.
134. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA and Bardeesy N (2011). "STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis." *Can. Res.* **71**: 1-10.
135. Lal G, Yin N, Xu J, Lin M, Schroppel S, Ding Y, Marie I, Levy DE and Bromberg JS (2011) Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of Foxp3 expression and Treg function. *Am. J. Transplant.* **11**: 203-14. PMC3079560
136. Wang D, Zavadil J, Martin L, Parisi F, Friedman E, Levy DE, Harding H, Ron D and Gardner LB (2011). Inhibition of nonsense mediated RNA decay by the tumor microenvironment promotes tumorigenesis. *Mol. Cell. Biol.* **31**: 3670-3680.
137. Wang WB, Levy DE and Lee CK (2011) Stat3 negatively regulates type I IFN-mediated antiviral response. *J. Immunol.* **187**: 2578-2585.
138. Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE and Bhardwaj N (2011) TLR4 engagement during TLR3-induced pro-inflammatory signaling in dendritic cells promotes IL-10-mediated suppression of anti-tumor immunity. *Cancer Res.* **71**: 5467-5476.
139. Farlik M, Rapp B, Marie IJ, Levy D.E., Jamieson AM and Decker T (2012) Contribution of a TANK-binding kinase 1-interferon (IFN) regulatory factor 7 pathway to IFN-gamma-induced gene expression. *Mol. Cell. Biol.* **32**: 1032-1043.

140. Wang Y and Levy DE (2012) Comparative evolutionary genomics of the STAT family of transcription factors. *JAK-STAT* **1**: 1-11.
141. Zhang L, Das P, Schmolke M, Manicassamy B, Wang Y, Deng X, Cai L, Tu BP, Forst CV, Roth MG, Levy DE, García-Sastre A, de Brabander J, Phillips MA and Fontoura BMA (2012) Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export. *J. Cell Biol.* **196**: 315-326.
142. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, and Schreiber RD (2012) STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. *Breast Cancer Res.* **14**: R16.
143. Lee JE, Yang YM, Liang FX, Gough DJ, Levy DE, and Sehgal PB (2012) Nongenomic STAT5-dependent effects on Golgi apparatus and endoplasmic reticulum structure and function. *Am J Physiol Cell Physiol* **302**: C804-820.
144. Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A (2012) Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. *Science* **336**: 1317-1321.
145. Poe SL, Arora M, Oriss TB, Yarlagadda M, Isse K, Khare A, Levy DE, Lee JS, Mallampalli RK, Chan YR, Ray A, and Ray P (2013) STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. *Mucosal Immunol.* **6**: 189-199.
146. Gatnovskiy L, Mita P, and Levy DE (2013) Human RVB1 is required for efficient transcription of type I IFN-stimulated genes. *Mol. Cell. Biol.* **33**: 3817-3825.
147. Gough DJ, Koetz L, and Levy DE (2013) The Mek-Erk pathway is necessary for serine phosphorylation of mitochondrial STAT3 during Ras-mediated transformation. *PLOS One* **8**: e83395.
148. Gough DJ, Marié IJ, Lobry C, Aifantis I, and Levy DE (2014) STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. *Blood* **124**: 2252-2261.
149. Pencik J, Schleder M, Gruber W, Unger C, Walker S, Chalaris A, Marié I, Hassler M, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer O, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner S, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L (2015) STAT3 regulated ARF expression suppresses prostate cancer metastasis. *Nature Comm.* **6**: 7736.
150. Garama DJ, Harris TJ, White CL, Rosello FJ, Abdul-Hay M, Gough DJ, Levy DE (2015) A synthetic lethal interaction between glutathione synthesis and mitochondrial reactive oxygen species provides a tumor specific vulnerability dependent on STAT3. *Mol. Cell. Biol.* **35**: 3646-3656.
151. Pham AM, Santa Maria FG, Lahiri T, Friedman E, Marie IJ, Levy DE. PKR Transduces MDA5-Dependent Signals for Type I IFN Induction (2016) *PLoS Pathog.* **12**: e1005489.

152. Wu J, Keng VW, Patmore DM, Kendall JJ, Patel AV, Jousma E, Jessen WJ, Choi K, Tschida BR, Silverstein KA, Fan D, Schwartz EB, Fuchs JR, Zou Y, Kim MO, Dombi E, Levy DE, Huang G, Cancelas JA, Stemmer-Rachamimov AO, Spinner RJ, Largaespada DA, Ratner N (2016). Insertional Mutagenesis Identifies a STAT3/Arid1b/beta-catenin Pathway Driving Neurofibroma Initiation. *Cell Rep.* **14**: 1979-90.
153. Daniels G, Zhang X, Zhong X, Santiago L, Wang LH, Wu X, Zhang JY, Liang F, Li X, Neubert TA, Steinke L, Shen Y, Basch R, Schneider R, Levy DE, Lee P (2016). Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation. *Oncotarget* **7**: 39556-39571.
154. Xiao Y, Zou Q, Xie X, Liu T, Li HS, Jie Z, Jin J, Hu H, Manyam G, Zhang L, Cheng X, Wang H, Marie I, Levy DE, Watowich SS, Sun SC (2017). The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. *J. Exp. Med.* **214**: 1493-1507.
155. Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono R, Perez L, Levy DE, Priol S, Carbone GM, Catapano CV (2017) Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. *Proc. Natl. Acad. Sci. USA* **114**: E4924-E4933.
156. Marié IJ, Chang HM, and Levy DE (2018). HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. *J. Exp. Med.* **215**: 3194-3212. PMID: PMC6279398.
157. Brambilla L, Lahiri T, Cammer M, Levy DE (2020) STAT3 Inhibitor OPB-51602 Is Cytotoxic to Tumor Cells Through Inhibition of Complex I and ROS Induction. *iScience* **23**: 101822. PMID: PMC7708861.
158. Lahiri T, Brambilla L, Andrade J, Askenazi M, Ueberheide B, Levy DE (2021) Mitochondrial STAT3 regulates antioxidant gene expression through complex I-derived NAD in triple negative breast cancer. *Mol. Oncol.* **15**: 1432-1449. doi: 10.1002/1878-0261.12928. PMID: 33605027

Invited papers and reviews:

159. Levy DE, Reich N, Kessler D, Pine R and Darnell JE Jr (1988) Transcriptional regulation of interferon-stimulated genes: a DNA response element and induced proteins that recognize it. *CSH Symp. Quant. Biol.* **LIII**: 799-802.
160. Levy DE (1988) Transcriptional response of interferon stimulated genes: role of the interferon stimulated response element and sequence-specific DNA binding proteins. *Interferons: Today & Tomorrow* **9**: 6-8.
161. Levy DE (1989) The regulation of interferon stimulated genes in responsive and non-responsive cells. *Trends in Interferon Research* **2**: 4-8.
162. Veals SA, Kessler DS, Josiah S, Leonard DGB and Levy DE (1991) Signal transduction pathway activating interferon-alpha-stimulated gene expression. *Brit. J. Haemat.* **79/S1**, 9-13.
163. Levy DE (1992) Cytoplasmic events in signal transduction leading to IFN α -induced gene expression, p. 161-173. In S. Baron, et al. (ed.), *Interferon: Principles*

and Medical Applications. The University of Texas Medical Branch at Galveston, Galveston.

164. Levy DE (1993) Induction of interferon- α -stimulated gene expression. *Forum Trends in Experimental and Clinical Medicine* **6**: 641-650.
165. Levy DE, Raz R, Durbin JE, Bluysen H, Muzaffar R and Pisharody S (1994) Cytoplasmic transcription factors: mediators of cytokine signaling. *Agents & Actions* **47**: 79-85.
166. Levy DE (1995) Interferon induction of gene expression through the Jak-Stat pathway. *Seminars in Virology* **6**: 181-189.
167. Bluysen HAR, Durbin JE and Levy DE (1996) ISGF3 γ p48, a specificity switch for IFN activated transcription factors. *Cytokine & Growth Factor Reviews* **7**: 11-17.
168. Levy DE (1997) The house that JAK/STAT built. *Cytokine & Growth Factor Reviews* **8**: 81-90.
169. Levy DE (1998) Stat protein complexes on IFN α -responsive promoter elements. *Meth. Enzymol.* **15**: 167-174.
170. Levy DE (1999) Physiological significance of Stat proteins: investigations through gene disruption in vivo. *Cell. Mol. Life Sci.* **55**: 1559-1567.
171. Levy DE and Gilliland DG (2000) Divergent roles of Stat1 and Stat5 in malignancy as revealed by gene disruptions in mice. *Oncogene* **19**: 2505-2510.
172. Levy DE and García-Sastre A (2001) The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. *Cytokine & Growth Factor Reviews* **12**: 143-156.
173. Levy DE, Marié I, Smith E, and Prakash A (2002) Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. *J. Inter. Cyt. Res.* **22**: 87-93.
174. Levy DE (2002) Whence interferon? Variety in the production of interferon in response to viral infection. *J. Exp. Med.* **195**: F15-F18.
175. Hessler JR and Levy DE (2002) Playing with a full committee. *Lab Animal* **31**: 19-20.
176. Levy DE and Lee CK (2002) What does Stat3 do? *J. Clin. Invest.* **109**: 1143-1148.
177. Levy DE and Darnell JE, Jr. (2002) STATs: transcriptional control and biological impact. *Nat. Rev. Mol. Cell Biol.* **3**: 651-662.
178. Levy DE (2003) STAT transcriptional activation mechanisms: communication with the basal transcriptional machinery. In *Signal Transducers and Activators of Transcription (STATs): Activation and Biology*, P. B. Sehgal, D. E. Levy, and T. Hirano, eds. (Dordrecht, Kluwer Academic Publishers), pp. 327-42.
179. Levy DE, Marié I and Prakash A (2003) Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. *Curr. Opin. Immunol.* **15**: 52-58.
180. Levy DE, Marié IJ (2004) RIGging an antiviral defense – it's in the CARDs. *Nat. Immunol.* **5**: 699-701.
181. Levy DE and Marie IJ (2005) How viruses elicit interferon production: triggering the innate immune response to viral infection. In *Modulation of Host*

- Gene Expression and of Innate Immunity by Viruses*, J.-P. Chaugeux, and P. Palese, eds. (Dordrecht, Kluwer Academic Publishers), Chap. 2.
182. O'Shea JJ, Kanno Y, Chen X, and Levy DE (2005) Stat Acetylation-A Key Facet of Cytokine Signaling? *Science* **307**: 217-218.
 183. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, and Levy DE (2005) New and old functions of STAT3. A pivotal target for individualized treatment of Cancer. *Cell Cycle* **4**: 995-997.
 184. Levy D and Inghirami G (2006) STAT3: a multi-faceted oncogene. *Proc. Natl. Acad. Sci. USA* **103**: 10151-10152.
 185. Wang Y, Zhu W, and Levy DE (2006) Nuclear and cytoplasmic mRNA quantification by SYBR green based real-time RT-PCR. *Methods* **39**: 356-362.
 186. Schindler C, Levy DE and Decker T (2007) JAK-STAT signaling: from interferons to cytokines. *J. Biol. Chem.* **282**: 20059-20063.
 187. Levy DE and Loomis CA (2007) STAT3 signaling and the hyper-IgE syndrome. *N. Engl. J. Med.* **357**: 165-1658.
 188. Levy DE and Marié IJ (2007) Signaling in the type I interferon antiviral innate immune response. *Nat. Immunol.* **8**: poster supplement.
 189. Gough DJ, Levy DE, Johnstone RW and Clarke CJ (2008) IFN γ signaling- Does it mean JAK-STAT? *Cytokine Growth Factor Rev* **19**: 383-394.
 190. Levy DE (2010) NF-kappaB-ISGF3 transcription factor cooperation: coincidence detector or memory chip? *Immunity* **33**: 1-2.
 191. Levy DE, Marié IJ and Durbin JE (2011) Induction and Function of Type I and III Interferon in Response to Viral Infection. *Curr Opin. Virol.* **1**: 476-486.
 192. Gough DJ, Sehgal P and Levy DE (2012) Nongenomic functions of STAT3. In *Jak-Stat Signaling: From Basics to Disease* (Decker T and Müller M, eds.). Springer-Verlag GmbH, Wien, pp. 91-98.
 193. Gough DJ, Messina NL, Clarke CJP, Levy DE and Johnstone RW (2012) Constitutive type I interferon modulates homeostatic balance through tonic signaling. *Immunity* **36**: 166-174.
 194. Levy DE and Marié IJ (2012) STATus report on tetramers. *Immunity* **36**: 553-555.

Book

Signal Transducers and Activators of Transcription (STATs). Activation and Biology. (2003) (Sehgal PB, Levy DE and Hirano T, eds.). Kluwer Academic Publishers, Dordrecht.